Compounds for the treatment and prevention of immune-mediated inflammatory diseases

CSIC and the University of Athens have found that secoiridoids, such as oleacein and oleocanthal, are useful to prevent or treat illnesses that result in immune-mediated gastrointestinal alterations.

A company dealing with pharmaceutical or nutraceutical compositions is sought for licensing agreement.

An offer for Patent Licensing

New wide anti-inflammatory treatment

Immune-mediated inflammatory disease (IMID) is a term used to define a group of clinically heterogeneous, unrelated disorders that are recognized to share common inflammatory pathogenic mechanisms. The incidence of these autoimmune and inflammatory diseases has increased worldwide, and is being considered a health concern associated to modern lifestyle, dietary habits, antibiotic intake and hygiene environment. Genetic factors also play a crucial role.

IMID is associated with comorbidities that extend beyond the primary target organ. Thus, many conditions in which symptoms are not localized to the gastrointestinal system often involve an underlying gastrointestinal dysfunction.

The researchers have found a new treatment for these intestinal alterations using oleacein and oleocanthal as agents that markedly reduced the major hallmarks of gastrointestinal dysfunction. This opens a new approach to the treatment of inflammatory bowel diseases, as well as multiple sclerosis, chronic obstructive pulmonary disease, Crohn’s disease, ankylosing spondylitis, systemic lupus erythematosus (SLE), and psoriasis/psoriatic arthritis and myocarditis.

Main innovations and advantages

- These products are natural substances that can be isolated from olives, and could be used as a supplement to the diet or in nutraceutical preparations
- May be used in combined therapies
- Preventive capabilities
- Cheap and easy available from natural sources (olives)

Patent Status
Spanish Patent application filed

For more information, please contact:
Juan P. Duque
Deputy Vice-Presidency for Knowledge Transfer.
Spanish National Research Council (CSIC)
Tel.: +34 983 54 89 40
E-mail: duque@csic.es comercializacion@csic.es